Floatz logo

101 assets in Exocrine Pancreatic Carcinoma

Therapeutic assets addressing Exocrine Pancreatic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Exocrine Pancreatic Carcinoma
Northwestern UniversityP2/3BBB (78)
Irinotecan
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2/3BBB (78)
Oxaliplatin
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2/3BBB (76)
Capecitabine
Exocrine Pancreatic Carcinoma
Zhejiang UniversityP2BB (68)
Vismodegib
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2BB (68)
Carboplatin
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2BB (67)
Vinorelbine Ditartrate
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2BB (67)
Olaparib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2BB (66)
Cis-Diamminedichloroplatinum Ii
Exocrine Pancreatic Carcinoma
Alliance for Clinical Trials in OncologyP2/3BB (64)
Cyclophosphamide
Exocrine Pancreatic Carcinoma
Essen BiotechP2B (61)
Durvalumab
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2B (60)
Letrozole
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Nivolumab
Exocrine Pancreatic Carcinoma
Emory UniversityP2B (60)
Palbociclib
Exocrine Pancreatic Carcinoma
Roswell Park Cancer InstituteP2B (60)
Pertuzumab
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Trastuzumab
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Trastuzumab Emtansine
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Adavosertib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2B (59)
Cediranib
Exocrine Pancreatic Carcinoma
University of NebraskaP2B (59)
Binimetinib
Exocrine Pancreatic Carcinoma
Roswell Park Cancer InstituteP2B (58)
Hydroxychloroquine
Exocrine Pancreatic Carcinoma
Northwestern UniversityP2B (58)
Pembrolizumab
Exocrine Pancreatic Carcinoma
Xencor, Inc.P2B (58)
Trametinib
Exocrine Pancreatic Carcinoma
University of UtahP2B (58)
Dasatinib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2B (57)
Lanreotide
Exocrine Pancreatic Carcinoma
SWOG Cancer Research NetworkP3B (57)
dn022150+ag　(stage ii)
Exocrine Pancreatic Carcinoma
Jiangxi Kvvit Pharmaceutical Co., Ltd.P2/3CCC (55)
Atezolizumab
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP1/2CCC (54)
Abemaciclib
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Capivasertib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ceb-01
Exocrine Pancreatic Carcinoma
CEBIOTEXP2CCC (53)
Crizotinib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Danvatirsen
Exocrine Pancreatic Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Defactinib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Entinostat
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P1/2CCC (53)
Exemestane
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Fexagratinib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fruquintinib
Exocrine Pancreatic Carcinoma
Fudan UniversityP2CCC (53)
Glipizide
Exocrine Pancreatic Carcinoma
Memorial Sloan Kettering Cancer CenterP2CCC (53)
Gsk-2636771
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
her3-dxd
Exocrine Pancreatic Carcinoma
Daiichi SankyoP2CCC (53)
Hrs-4642
Exocrine Pancreatic Carcinoma
Zhejiang UniversityP2CCC (53)
Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer
Exocrine Pancreatic Carcinoma
Zhejiang UniversityP2CCC (53)
Ipatasertib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Osimertinib
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pemigatinib
Exocrine Pancreatic Carcinoma
Sameek RoychowdhuryP2CCC (53)
Relatlimab
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Rivoceranib
Exocrine Pancreatic Carcinoma
Zhejiang UniversityP2CCC (53)
Showing 1 to 50 of 101 assets
PreviousPage 1 of 3Next